Extended Data Fig. 7: Anti-adenovirus antibody levels.
From: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
a, Immunoglobulin G (IgG) levels before and after treatment across dose cohorts in the trial. b, IgG levels across dose cohorts in thet trial over time. Data shown are mean +/− SD. c-d, Shown are Kaplan-Meier survival curves with associated 95%CI. Patients stratified according to level of response in Anti-Ad5 IgG levels after treatment compared to baseline levels. + denote censored data. c, Shows survival using 4-fold threshold. d, Shows survival using 10-fold threshold.
